FY2029 Earnings Estimate for RCUS Issued By Wedbush

Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) - Investment analysts at Wedbush issued their FY2029 EPS estimates for Arcus Biosciences in a report issued on Tuesday, February 18th. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of $3.03 for the year. Wedbush currently has a "Outperform" rating and a $36.00 target price on the stock. The consensus estimate for Arcus Biosciences' current full-year earnings is ($3.20) per share.

A number of other equities analysts also recently issued reports on the company. Morgan Stanley dropped their price target on Arcus Biosciences from $36.00 to $25.00 and set an "overweight" rating on the stock in a research report on Tuesday. HC Wainwright lowered their price objective on shares of Arcus Biosciences from $20.00 to $18.00 and set a "neutral" rating for the company in a research note on Tuesday. Bank of America cut their target price on shares of Arcus Biosciences from $22.00 to $17.00 and set a "neutral" rating on the stock in a research report on Wednesday. Finally, Barclays upped their price target on shares of Arcus Biosciences from $25.00 to $29.00 and gave the stock an "overweight" rating in a research report on Friday, October 25th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $29.50.

Arcus Biosciences Trading Up 3.0 %

NYSE:RCUS traded up $0.32 during midday trading on Thursday, hitting $11.06. The stock had a trading volume of 1,238,479 shares, compared to its average volume of 894,829. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. The stock has a 50-day moving average of $13.92 and a 200 day moving average of $15.55. The company has a market capitalization of $1.01 billion, a price-to-earnings ratio of -3.51 and a beta of 0.84. Arcus Biosciences has a one year low of $10.63 and a one year high of $20.31.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of RCUS. Gilead Sciences Inc. purchased a new position in shares of Arcus Biosciences during the 4th quarter valued at approximately $447,610,000. Boxer Capital Management LLC acquired a new stake in Arcus Biosciences during the fourth quarter valued at $23,857,000. Braidwell LP purchased a new position in Arcus Biosciences in the fourth quarter valued at $11,943,000. Millennium Management LLC raised its position in shares of Arcus Biosciences by 277.1% in the fourth quarter. Millennium Management LLC now owns 924,369 shares of the company's stock worth $13,764,000 after acquiring an additional 679,267 shares during the period. Finally, Parkman Healthcare Partners LLC boosted its stake in shares of Arcus Biosciences by 146.9% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,025,754 shares of the company's stock worth $15,684,000 after acquiring an additional 610,219 shares in the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CFO Robert C. Goeltz II sold 3,594 shares of the company's stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $15.00, for a total value of $53,910.00. Following the sale, the chief financial officer now owns 60,138 shares in the company, valued at $902,070. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.30% of the stock is currently owned by corporate insiders.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.